A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
By K. Papp, S. Tyring, M. Lahfa, J. Prinz, C. E. Griffiths, A. Nakanishi, R. Zitnik, P. van de Kerkhof, Linda Melvin. British Journal of Dermatology, 2005
712 citations recorded by the source corpus.
Subfields: Immunology, Oncology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/1f720d0a1afdbb3c46d456f776100a093dc3567f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008, background): “Rebound does not typically occur when etanercept is discontinued.(123,126,128) An important issue to consider with etanercept, as with other TNF inhibitors, is the potential loss of efficacy over time, possibly related to the development of antibodies.”